Neurosense Therapeutics Ltd. (NRSN) AI Stock Analysis

• Market Cap: $48.70M
• Dividend Yield: N/A
• Average Volume (3M): 341.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: N/A
• EPS Growth: 31.09%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 23,988,668
• 10 Day Avg. Volume: 248,852
• 30 Day Avg. Volume: 341,721
• PEG Ratio: -0.32
• Price to Book (P/B): 17.99
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.90
• 1Y Price Target: $14.00
• Price Target Upside: 589.66% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 30 Underperform
• Price Target: ―

Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.

Positive Factors

Research and Development

NeuroSense is continuing to progress the development of PrimeC for treating amyotrophic lateral sclerosis (ALS) and has completed the scale-up of its manufacturing process to commercial scale.

Negative Factors

Financial Constraints

NRSN finished with $3.4M in cash and equivalents, which is not sufficient to fund the Phase 3 trial.

Funding Challenges

Capital constraints, including 'baby shelf' limitations, make it difficult to raise sufficient capital to fully finance the Phase 3 trial.

Regulatory Challenges

Shares are downgraded to Hold due to the unlikelihood of pursuing an Accelerated Approval pathway in the U.S. for PrimeC.

Neurosense Therapeutics Ltd. Business Overview & Revenue Model

Company Description

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

How the Company Makes Money

Neurosense Therapeutics Ltd. generates revenue primarily through funding and partnerships related to its research and development activities. The company may secure revenue from licensing agreements, where larger pharmaceutical companies pay upfront fees, milestone payments, and royalties for the rights to develop and commercialize its drug candidates. Additionally, Neurosense might receive government grants or private funding to support its research initiatives. As its products progress through clinical trials and towards market approval, the company may also enter into strategic collaborations that contribute to its financial growth.

Neurosense Therapeutics Ltd. Financial Statement Overview

Summary

Neurosense Therapeutics Ltd. has significant financial challenges, including a lack of revenue, consistent operational losses, a weak balance sheet, and cash flow management issues.

Income Statement

Neurosense Therapeutics Ltd. has no revenue streams, resulting in negative gross profit and net income over the years. The company consistently operates at a loss, with EBIT and EBITDA margins being negative. The absence of revenue and declining net income indicates significant challenges in achieving profitability.

Balance Sheet

The company has a weak balance sheet with negative stockholders' equity in recent years, indicating potential issues with financial stability. The debt-to-equity ratio cannot be calculated due to negative equity, emphasizing the need for improved financial structure. Total liabilities exceed total assets, posing a risk to financial solvency.

Cash Flow

Neurosense Therapeutics Ltd. is experiencing negative free cash flow, with operating cash flow consistently negative. The free cash flow growth is volatile with significant fluctuations, highlighting cash management challenges. The company relies heavily on financing activities to manage its cash flow requirements.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-22.00K	-97.00K	-89.00K	-3.00K	-3.00K
EBITDA	-9.88M	-9.64M	-13.38M	-2.88M	-2.83M
Net Income	-10.21M	-10.11M	-10.49M	-2.50M	-2.83M
Balance Sheet
Total Assets	4.58M	3.18M	7.71M	11.43M	779.00K
Cash, Cash Equivalents and Short-Term Investments	3.38M	2.64M	7.09M	11.06M	699.00K
Total Debt	73.00K	142.00K	211.00K	1.83M	0.00
Total Liabilities	1.99M	4.94M	2.09M	2.42M	120.00K
Stockholders Equity	2.58M	-1.87M	5.62M	9.01M	659.00K
Cash Flow
Free Cash Flow	-10.14M	-8.38M	-7.66M	-1.56M	-704.00K
Operating Cash Flow	-10.13M	-8.35M	-7.59M	-1.54M	-695.00K
Investing Cash Flow	1.00K	3.47M	-3.54M	-17.00K	-9.00K
Financing Cash Flow	10.91M	3.98M	3.69M	11.90M	508.00K

Neurosense Therapeutics Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRSN, the sentiment is Positive. The current price of 2.03 is above the 20-day moving average (MA) of 1.99, above the 50-day MA of 1.90, and above the 200-day MA of 1.30, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 52.44 is Neutral, neither overbought nor oversold. The STOCH value of 55.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NRSN.

Neurosense Therapeutics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LGVN	61 Neutral	$26.12M	―	-167.57%	―	127.51%	71.16%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
GBIO	46 Neutral	$29.03M	―	-70.06%	―	146.47%	57.85%
LTRN	45 Neutral	$45.62M	―	-75.66%	―	―	-31.16%
PASG	44 Neutral	$17.88M	―	-83.73%	―	―	42.39%
CGTX	41 Neutral	$49.90M	―	-161.93%	―	―	-0.38%
NRSN	30 Underperform	$48.70M	―	-2880.11%	―	―	31.09%